Fig. 3From: Multi-country clinical practice patterns, including use of biomarkers, among physicians’ treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC)a, b Physician proportions (n = 508) reporting current management approaches for NMIBC patients, split by ‘intermediate-‘ and ‘high-risk’Back to article page